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INTRODUCTION 
Neurodegenerative diseases represent a wide range of diseases of various 
nature, caused by the gradual death of certain groups of nerve cells and charac-
terised by steadily progressing neurological deficits, including motor disorders, 
psychoemotional, and cognitive (up to dementia) disorders. The most common 
neurodegenerative diseases are Alzheimerʼs disease (AD), Parkinson's disease 
(PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (AML). 
Currently, the world has seen a rapid increase in patients with neurodegene-
rative diseases. According to a report by the World Health Organization (WHO) 
[1,2], the total number of people with dementia worldwide amounted to 47 
million in 2015, increasing to 75 million by 2030, and up to 132 million by 
2050. According to the WHO, AD and other forms of dementia are also among 
the ten leading causes of death in the world [3]. 
The main feature of these diseases is their long-term asymptomatic develop-
ment, and the clinical symptoms characteristic of each disease appear after the 
almost complete degradation of the key regulatory neurons and the depletion of 
compensatory brain reserves. To date, the exact cause of neuronal death during 
neurodegeneration is unknown, however, some genetic and environmental 
factors have been associated with this type of disease. The main factors include 
the life expectancy and environmental pollution [4]. There are presently no 
radical treatments for the neurodegenerative disorders. Current methods of the 
treatment are symptomatic and aim to increase the activity of surviving neurons 
in order to minimise the clinical manifestations of the degenerative process. 
Neurological diseases have a significant impact not only at the individual 
level but also on the whole society, since the treatment and rehabilitation of 
patients places a heavy financial burden on society and the state. Thus, in 2015 
the worldwide dementia costs amounted to $818 billion, and by 2030, the cost 
of caring for people with dementia is estimated to have risen to $2 trillion [2]. 
The rapid growth of patients, the increase in the cost of treatment and 
support for those suffering from neurodegenerative diseases and their loved 
ones, the increase in life expectancy, and the consequent ageing of the popula-
tion make the fight against neurodegenerative diseases one of the major global 
challenges of the 21st century [5]. In the fight against neurodegeneration, several 
approaches are currently being used to create and search for drugs with neuro-
protective properties. 
1)  Directed construction of drugs using rational computer design based on the 
knowledge about the molecular mechanisms of the pathogenesis of neuro-
degenerative diseases [6,7]. 
2)  Search among available medicines, regardless of their field of application 
[8]. 
3)  Isolation of physiologically active substances with neuroprotective proper-
ties from body tissues and their chemical modification [9]. 
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4)  A combination of the above three approaches, structural and conformational 
optimisation of a drug molecule [10]. 
This thesis provides examples of the use of modern methods of molecular 
modelling in the development of new drugs against neurodegenerative diseases 
as well as the use of computational chemistry methods to study and understand 
the mechanisms of action of potential drug candidates with their biological 
targets. 
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1. LITERATURE OVERVIEW 
1.1. Current protein targets used for in silico drug design 
against neurodegenerative diseases 
With an improvement in the quality of life and medical services, life expectancy 
is also increasing, which in turn leads to an ageing population and the spread of 
age-related diseases, particularly neurodegenerative diseases. Many organisa-
tions and individual laboratories are working on the development of treatment 
for neurodegenerative diseases, but there is still no effective therapy and drugs. 
The main obstacles are the complexity of the brain and its working mechanisms, 
the insufficient availability of resources and ethical limitations. Nevertheless, in 
recent decades, advances in computer technology have allowed in silico experi-
ments to have a significant impact on the development of novel drugs and drug 
candidates [11–13]. 
Nowadays, computer-aided drug design (CADD) is widely exploited in the 
development of new drugs. The first step in this approach is the identification of 
the target protein. A sufficient number of protein targets have been found to be 
directly or indirectly associated with neurodegenerative diseases [14]. Such a 
variety of potential targets arises from the fact that most neurodegenerative 
diseases are characterised by multiple disorders. The target proteins that have 
been currently used in computer design are listed in Table 1. 
 
Table 1. Current protein targets related to neurodegenerative diseases and used for in 
silico approaches. 
Disease Targets Computationally derived drugs Ref. 
AD 
AChE 
Flavonoid derivatives, 
macluraxanthone, 
kaempferol, rutin, quercetin, 
pyridopyrimidine, 6-chloro-
pyridonepezil, pyridonepezil, and 
piperazine derivatives 
[15,16] 
BuChE - [11,17] 
NMDA Memantine [18] 
BACE1 AF267B, OM00-3 and OM99-2 [19,20] 
SERT - [21] 
GSK3β  - [22] 
Muscarinic and 
nicotinic AChE 
receptors 
- [23] 
γ-Secretase: 
presenilin I - [24,25] 
Calcium-permeable 
AMPA receptors 
(CP-AMPARs) 
- [26,27] 
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Table 1. (continued) 
Disease Targets Computationally derived drugs Ref. 
PD 
LRRK2 
LRRK2 kinase inhibitors, 
pyrroloquinoline quinone, 
dopamine related compounds 
[28] 
SNCA - [29] 
PINK1 - [30] 
PARK2 - [17] 
DJ-1 - [31] 
ALS 
Copper-zinc 
superoxide dismutase 
Hesperidin, 
2,3,5,4’-tetrahydroxystilbene-2-O-
𝛽-D-glucoside (THSG) 
[32,33] 
CASP-3 - [34] 
CDC7 - [35] 
p38 MAPK - [36] 
SCN8A Riluzole [37] 
HD 
HTT-interacting 
protein 1 - [38] 
Postsynaptic density-
95 - [39] 
FIP-2 - [40] 
 
1.2. Neurotrophic factors in the therapy of 
neurodegenerative diseases 
Neurotrophic factors are essential proteins that regulate the proliferation, sur-
vival, and differentiation of cells in the peripheral and central nervous system 
[41]. At the same time the neurotrophic factors have neuroprotective functions. 
Neurotrophic factors comprise three families of growth factors: the NGF family 
(neurotrophins) [42], glial cell line–derived neurotrophic factor (GDNF) family 
ligands [43], and the heterogeneous group of molecules that belong to the cyto-
kine family [44]. More recently, unconventional neurotrophic factors, such as 
cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte-  
derived neurotrophic factor (MANF), have been described [45]. 
The high potency of neurotrophic factors as well as their role in survival of 
neurons makes them rational therapeutic agents for neurodegenerative diseases. 
However, their clinical use is limited because of difficulties in protein delivery 
and pharmacokinetics in the central nervous system [46]. The first clinical trials 
involving neurotrophic factors as drugs were conducted back in the 1990s, but 
none of them received permission from the authorities due to the lack of speci-
fic targeting, difficulties in achieving an effective dose, and side effects [47]. 
Unsuccessful clinical trials led to a reassessment of the suitability of neuro-
trophic factors in neurodegenerative diseases as well as to a more thorough 
study of the physiological basis of the pharmacology of neurotrophic factors as 
a potential biological target on the development of neuroprotective drugs [48]. 
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1.3. Glial cell line-derived neurotrophic factor 
GDNF promotes the survival of several types of neurons, such as dopami-
nergic and motor neurons [52]. The GDNF signalling has also an important role 
in the kidney development [53] and spermatogenesis [54]. GDNF has a neuro-
protective effect and induces fiber outgrowth as demonstrated in rat and primate 
models of PD [55-59]. It was also shown in rat model of ALS that ex vivo gene 
delivery of GDNF slows degeneration of the motoneurons [60]. Forlenza et al. 
demonstrated that the GDNF level decreases in Alzheimer’s patients, especially 
those with cognitive impairments [61]. The injection of GDNF into the brain of 
rabbits protected them against Alzheimer’s-like symptoms caused by aluminium 
exposure [62]. GDNF has also beneficial effect in the case of age-related neuron 
damage [63,64]. In the clinical trials of GDNF, beneficial effects have been 
described for patients, which have been followed for longer periods, but the 
method of delivery of the protein into brain has become a critical issue [65-67]. 
 
 
1.4. Earlier attempts to find small-molecule mimetics of 
neurotrophic factors 
As described in Section 1.2, the use of neurotrophic factors and their receptors 
in the treatment of neurodegenerative diseases has several problems and 
constraints. Subsequently, many studies of neurotrophic factors as therapeutic 
targets in neurodegenerative diseases were concentrated on the search for small 
molecules that have a selective effect and mimic the effect of neurotrophic 
factors. Thus, Saragovi et al. suggested that selective Trk-activating agents that 
circumvent p75 binding and activation would be neuroprotective. They created 
small-molecule mimetics of neurotrophins [68-75], agonistic monoclonal anti-
bodies (mAbs) [76-79], and small-molecule mimetics of the mAbs [75-82] that 
exhibited neuroprotective activity in vivo. Later, other groups have reported 
about several TrkB small-molecule agonists, and TrkB and TrkC agonistic 
mAbs that demonstrate the protective effect in the 1-methyl-4-phenyl-1,2,3,6-
Glial cell line-derived neurotrophic factor (GDNF) is the first identified member 
of the GDNF family of ligands (GFL) and was primarily isolated from the rat B49 
glial cell line in 1993. Structurally, GDNF is a glycosylated and disulphide-bonded 
homodimer with the molecular weight approximately 33–45 kDa [49]. The 
GDNF signalling is mediated by a multicomponent receptor complex consisting 
of RET receptor tyrosine kinase and a glycosyl phosphatidylinositol (GPI)-linked 
ligand-binding subunit known as GDNF family receptor α (GFRα) [50]. GDNF 
specifically binds to GFRα1. The complex of homodimers of GFL and GFRα1 
brings two molecules of RET together, triggering transphosphorylation of 
specific tyrosine residues in their tyrosine kinase domains and intracellular 
signalling [51]. RET, in turn, activates several intracellular signalling cascades, 
which regulate cell survival, differentiation, proliferation, migration, chemo-
taxis, branching morphogenesis, neurite outgrowth, and synaptic plasticity. 
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tetrahydropyridine (MPTP) neurotoxicity mouse model of PD [83-89] and in the 
transgenic R6/2 and BACHD mouse models of HD [90,91]. One of the 
Trk-selective small-molecule agonists found by Saragovi et al. is presently in 
Phase 3 clinical trials for an ophthalmic indication, TrkC-selective mAb agonist 
is in preclinical studies for ALS, and Trk-selective agonistic mAbs and neuro-
trophins mutants are under investigation for neurosensory hearing loss [48]. 
The small-molecule agents related to other neurotrophic factors have been 
also reported. In 2003, Tokugawa et al. described compound XIB4035 as a 
GFRα1 agonist [92], but it was later shown to be a GFRα1 modulator, able to 
potentiate signalling in the presence of GDNF [93,94]. Doonan et al. found that 
the synthetic progestin Norgestrel has a neuroprotective effect in the rat model 
of retinal degeneration diseases (Retinitis Pigmentosa) [95]. Sidorova et al. 
demonstrated that small-molecule agonists of GFRα1, BT13, and BT18 have 
RET modulatory activity and efficiency in rat model of neuropathy [93,96]. 
Although the first clinical trials with neurotrophic factors were initiated 25 
years ago, the applicability of neurotrophic factors in the treatment of neuro-
degenerative diseases is currently unclear [97]. Thus, the development of 
small-molecule mimetics or agonists of neurotrophic factors is of great interest, 
the use of small-molecule compounds may facilitate the achievement of the 
required pharmacokinetic properties and biological activity. 
 
 
1.5. Earlier attempts to find multiple target drug 
candidates against neurodegenerative diseases 
Alzheimer’s disease (AD) is the most common neurodegenerative disorder for 
which there are currently no effective drugs. The development of new therapies 
is hindered because a deeper understanding of the exact pathophysiology and 
molecular mechanism of AD is lacking. The pathological features of AD 
include amyloid deposition [98], astrogliosis [99], tau protein hyperphospho-
rylation and accumulation [100,101], neuronal dystrophy [102], oxidative stress 
[103], biometal dyshomeostasis, decline in acetylcholine levels [104], etc. 
Because a variety of potential biological targets has been related to this disease, 
the identification of multitarget compounds against AD is one of the promising 
approaches in the drug development [105]. The multitarget drugs acting simul-
taneously against several adverse factors of AD could be more effective and 
may possess a safer profile compared to single-target drugs. 
Several attempts have been made to find multitarget compounds against AD. 
Sharma et al. had carried out virtual screening using molecular docking and 
molecular dynamics and identified several N-benzylpiperidine analogues that 
have inhibitory activity against AChE and BACE1 [106]. A series of hydro-
xylated chalcones were computationally designed and synthesised by Cong et 
al. as dual-functional compounds that inhibit simultaneously the amyloid-β 
(Aβ) peptide aggregation as well as the ferroptosis [107]. Fang et al. developed 
some tetrahydroisoquinoline-benzimidazoles that inhibited BACE1 and ex-
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hibited significant anti-neuroinflammatory activity and good blood-brain  
barrier penetration in artificial membrane permeation assay [108]. Proceeding 
from computational molecular docking and molecular dynamics simulations, 
Gonzalez-Naranjo et al. had developed a new family of indazolylketones with a 
multitarget profile against cholinesterase and BACE1. Altogether nine inda-
zolylketones with significant multifunctional activity against the above targets 
were discovered. The subsequent pharmacological tests showed that some of 
indazolylketones of the final set act as CB2 cannabinoid agonists and simul-
taneously inhibit of BuChE and/or BACE1 [109]. Novel isoflavone analogues 
were found in the work by Wang et al. as multitarget-directed ligands for 
histamine 3 receptor (H3R) and AChE [110]. Despite limited initial success, the 
multitarget approach remains a very promising direction in the development of 
novel drugs. 
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2. AIMS OF THE STUDY 
The main objective of this thesis is the application of the different molecular 
modelling techniques in drug discovery against neurodegenerative diseases. 
This work is focused on the development and search for new drug candidates 
against the most common neurodegenerative diseases, namely Alzheimer’s and 
Parkinson’s diseases. 
Paper I The main objective of this paper is the study of the possible 
mechanism of interaction between the known agonists and the 
GFRα1-RET complex using molecular modelling techniques; 
Paper II The aim of this paper is the molecular design of the potential 
GFRα1 agonists using the structure-based drug design; 
Paper III The aim of this paper is to identify new potentially active 
compounds for three protein targets (TrkA, NMDA, and LRRK2) 
using a combination of different QSAR and molecular modelling 
methods; 
Paper IV The aim of this paper is a development and application of a 
combination of the QSAR and molecular modelling methods in the 
design of multitarget drug candidates against Alzheimer’s disease. 
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3. MODELLING AND EXPERIMENTS 
3.1. Computational methods 
3.1.1. Computational methods in drug design 
The process of finding and developing drugs is a rather time-consuming and 
expensive process. Over the past three decades, computer-based drug detection 
and design methods have played an increasingly significant role in the develop-
ment of new therapeutically active compounds. The computer-aided drug design 
(CADD) methods help to accelerate the long process of developing new medi-
cines and reduce their cost. Notably, CADD technology has played an impor-
tant role in the discovery of many pharmaceutical products that have been 
approved by the regulatory agencies and reached the consumer market 
[111,112]. The principal tools for rational drug design include molecular 
docking and the related virtual screening of large chemical compound libraries, 
molecular dynamics (MD) simulations and quantitative structure–activity 
relationship (QSAR) methods, such as multilinear regression or machine 
learning. The molecular docking and molecular dynamics belong to the class 
so-called target-based methods, whereas QSAR makes the foundation of 
ligand-based methods. The research in the present thesis was carried out using 
mostly the target-based methods. The technical details of the application of 
these methods are described in the following sections of this Chapter.  
 
 
3.1.2. Preparation of protein target structures and 
small-molecule ligands 
The initial step in using the molecular modelling methods is the preparation of 
protein target structures and small-molecule ligands. The raw crystal structures 
of protein targets are available from Protein Data Bank (PDB) [113]. A list of 
the crystal structures of proteins used in the present thesis is given in Table 2. 
Before modelling, all reported crystal structures of proteins were pre-treated 
using Schrödinger Protein Preparation Wizard [114]. Hydrogen atoms were 
automatically added to the proteins and water molecules were removed. In 
Paper I, the 2D chemical structures of the small-molecule ligands were 
converted into the 3D structures and optimised by molecular mechanics MM+ 
field using HyperChem 8.0 [115]. PDB files for molecular docking were created 
using the “Online SMILES Translator and Structure File Generator” [116]. In 
Papers III and IV, the 3D structures of the ligands were generated using 
LigPrep procedure from the Schrödinger Suite [117]. The OPLS_2005 force 
field of LigPrep was used in all ligand preparation steps. Generation of all 
possible states and ionisation states was enumerated for each ligand using Epik 
at a pH of 7.0 ± 2. PDB files were created from lowest energy conformers for 
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each ligand. PDBQT files for molecular docking procedure were generated 
from the corresponding PDB files using the AutoDock Tools software [118]. 
 
Table 2. List of the used crystal structures of the studied proteins. 
PDB 
ID Name 
Resolution, 
Å Method Released Ref. 
4UX8 GDNF-GFRα1-RET complex 24 
Electron 
microscopy 2014 [119] 
3FUB GDNF-GFRα1 complex 2.35 X-ray diffraction 2009 [120] 
4U8Z 
MST3 in complex with a 
pyrrolopyrimidine 
inhibitor (PF-06447475) 
1.63 X-ray diffraction 2015 [121] 
5TP9 
Human GluN1/GluN2A 
LBD in complex with 
GNE9178 
2.4 X-ray diffraction 2016 [122] 
4AOJ Human TrkA in complex with the inhibitor AZ-23 2.75 
X-ray 
diffraction 2012 [123] 
4EY6 Human AChE in complex with (-)-galantamine 2.39 
X-ray 
diffraction 2012 [124] 
6EQM Human BACE-1 in complex with CNP520 1.35 
X-ray 
diffraction 2018 [125] 
1PYX Human GSK-3 beta in complex with AMP-PNP 2.4 
X-ray 
diffraction 2003 [126] 
5I6X ts3 human SERT in complex with paroxetine 3.14 
X-ray 
diffraction 2016 [127] 
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3.1.3. Molecular docking and virtual screening 
Molecular docking is a widely used computational method in drug design. The 
essence of this method is to model the relative position between a small mole-
cule (ligand) and a studied target protein (receptor). Currently, a variety of soft-
ware packages is available for molecular docking [128]. To find the best 
binding mode between a small molecule and a receptor, a molecular docking 
algorithm takes into account the geometric complementarity and flexibility of a 
ligand and/or a receptor as well as their interatomic interactions (i.e., hydrogen 
bonds and hydrophobic contacts). Each docking procedure is based on a specific 
search algorithm, such as incremental construction (IC) [129,130], genetic 
algorithm (GA) [131,132], Monte Carlo [133], etc. After obtaining the best 
orientation using a scoring function (Dock Score, Glide Score, Chem Score, etc. 
[134,135]), which approximately describes the interaction energy of a small 
molecule with a target protein, the docking program ranks the studied sub-
stances. 
In Papers I and II, the molecular docking was carried out using AutoDock 
Vina 1.1.2 (hereinafter referred to as Vina) [136] that applies an iterated local 
search global optimiser [137,138]. A series of steps consisting of the geometry 
optimisation is executed in order to obtain the ligand-receptor complex 
conformation with the lowest binding energy. Each step is validated according 
to the Metropolis criterion [136]. For the local geometry optimisation, the Vina 
software uses Broyden-Fletcher-Goldfarb-Shanno (BFGS) [139] method. The 
BFGS, like other quasi-Newton optimisation methods, uses not only the value 
of the interaction energy but also its gradient, i.e., the derivatives of the scoring 
function with respect to its arguments. The final binding ligand-protein 
conformation is characterised by its energy Ebind, free energy  ΔGbind or ligand 
efficiency LE: 
     𝐿𝐸ሺ𝐸ሻ =  ா್೔೙೏ே೓             (1) 
     𝐿𝐸ሺ𝛥𝐺ሻ =  ∆ீ್೔೙೏ே೓            (2) 
where Nh denotes the number of non-hydrogen atoms in the ligand. 
In Paper IV, Vina was used for the high throughput virtual screening 
(HTVS) [140] of the chemical compound libraries. During the screening, the 
docking parameters were used in their default values. After the HTVS pro-
cedure, the results were automatically sorted from lowest to highest energy, and 
compounds with binding energy highest than -8.0 kcal/mol were excluded from 
further analysis [141]. 
In Papers III and IV, the HTVS was carried out using the Glide virtual 
screening workflow module of the Schrödinger Suite (hereinafter referred to as 
Glide HTVS) [142,143] that applies a series of hierarchical filters to search for 
possible locations of the ligand in the active-site region of the receptor. At the 
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next step, Glide produces a set of initial ligand conformations that are selected 
from an exhaustive enumeration of the minima in the ligand torsion-angle space 
and are represented in a compact combinatorial form. Based on these ligand 
conformations, initial screens are executed throughout the phase space available 
to the ligand to determine the location of the perspective positions of the ligand. 
This pre-screening significantly reduces the region of phase space over which 
computationally expensive energy and gradient evaluations will be later done, 
while avoiding the use of stochastic methods [144]. Glide is a force-field based 
docking program that uses an optimised potential for liquid simulations, e.g. 
OPLS force fields. The potential energy of the system is represented as a sum of 
bond, angle, torsion, and nonbonded terms in the OPLS family of force fields 
[145-149]. Molecular geometry and vibrational frequencies are mainly deter-
mined by the bond and angle terms and the torsion term describes the energetics 
of conformational rearrangement of the system. The nonbonded terms include 
electrostatic interactions calculated using atom-centred partial charges and a 
Lennard-Jones potential [150] representing dispersion and electronic repulsion. 
The Glide HTVS procedure includes three steps: (i) docking with HTVS 
precision level, (ii) docking with standard precision level, and (iii) docking with 
an extra precision. All small-molecule ligands were docked flexibly with five 
docking poses generated for each ligand. Only the best scoring pose was kept 
for the next step. After each step, the top 30% of ligands with the best docking 
score were automatically selected for the next step. In this way, a set of 500 
compounds for each target were obtained. 
In Papers III and IV, the binding interfaces of studied proteins were 
identified using Schrödinger Glide Grid Generation [151]. The obtained data 
were also used for docking/virtual screening with Vina. 
 
 
3.1.4. Molecular dynamics simulations 
The molecular dynamics (MD) simulations are one of the most powerful 
computational methods to model physical and biological systems. Molecular 
dynamics methods allow to calculate the classical trajectories of individual 
atoms and to study the dynamics of the interaction of particles in condensed 
systems at the molecular level. The molecular dynamics has been widely used 
to study the structural and dynamic properties of proteins, nucleic acids, lipid 
membranes, etc. In Papers I–IV, the MD simulations were used to study in 
detail the binding of small molecules to the target proteins. 
The simulations were carried out using Desmond program package of 
Schrödinger LLC [152]. The simulations were executed in cubic simple point 
charge SPC [153] water box using OPLS_2005 force field parameters (see 
Section 3.1.3) [154]. Sodium and chloride ions were placed in the solvent to a 
concentration 0.15 M, thereafter, to achieve electroneutrality, additional ions 
were added to the system. The isothermal-isobaric (NPT) ensemble with the 
temperature 300 K and a pressure 1 bar was applied in all runs. The simulation 
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length was 50 ns with relaxation time 1 ps for each studied protein–protein 
complex conformation. The long-range electrostatic interactions were calculated 
using the particle mesh Ewald (PME) method [155]. The cutoff radius in 
Coulomb interactions was 9.0 Å. The Martyna-Tuckerman-Klein chain coupling 
scheme [156] with a coupling constant of 2.0 ps was used for the pressure 
control and the Nosé-Hoover chain coupling scheme [156] for the temperature 
control. Nonbonded forces were calculated using a reversible reference system 
propagator algorithm (RESPA) integrator, where the short-range forces were 
updated every step and the long-range forces were updated every three steps. 
The trajectories were saved at 50 ps intervals. The behaviour and interactions 
between the proteins were analysed using the Simulation Interaction Diagram 
tool implemented in Desmond molecular dynamics package. The stability of 
MD simulations was monitored by checking the root-mean-square deviation 
(RMSD) of the protein atom positions in time. 
 
 
3.1.5. Binding energy estimation by MM/GBSA method 
The binding free energy is an important property characterising various 
(bio)molecular processes, such as protein folding, molecular association, inter-
actions between small-molecule ligands and proteins, etc. Therefore, an accu-
rate assessment of the free energy is one of the most important tasks in 
biomolecular studies. The theoretical calculations of the free energies of bio-
molecular systems by numerical simulation are becoming more and more 
widespread, as the experimental measurements of the thermodynamic properties 
of these systems can be often cumbersome and time-consuming [157]. In 
CADD, the binding free energy is used to characterise the binding strength 
between a receptor and a small-molecule ligand. Different theoretical methods 
of binding free energy calculations, especially the end-point methods have been 
successfully used in drug design [161-163]. These methods are based on 
samplings of the final states of a system, being much less expensive than using 
molecular dynamics and more accurate than most docking scoring functions. 
The molecular mechanics Poisson-Boltzmann surface area (MM/PBSA) and 
molecular mechanics generalised Born surface area (MM/GBSA) methods 
developed by Kollman et al. are the most frequently used end-point free energy 
methods [164-166]. These methods have been used to evaluate docking poses, 
determine structural stability, and predict binding affinities of the ligand- 
receptor complexes. 
MM/PBSA and MM/GBSA utilise the decomposition of the free energy of 
binding [167-169] into the individual terms arising from the following sum: 
𝐺 = 𝐸௕௜௡ௗ + 𝐸௘௟ + 𝐸௩ௗௐ + 𝐺௣௢௟ + 𝐺௡௣ − 𝑇𝑆     (3) 
where the first three terms are standard MM energy terms from bonded (bond, 
angle, dihedral), electrostatic, and van der Waals interactions, respectively. Gpol 
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and Gnp are the polar and nonpolar contributions to the solvation free energies, 
respectively. In MM/GBSA approach, Gpol is obtained using the generalised 
Born (GB) model [170], whereas the nonpolar term is estimated from a linear 
relation to the solvent accessible surface area of the ligand. The last term in the 
equation (3) is the absolute temperature (T), multiplied by the entropy (S), 
estimated from the normal-mode analysis of the vibrational frequencies. 
 
3.2. Enzyme inhibition assays 
In Paper IV, the activity of the selected compounds against AChE, BACE1, and 
GSK3β was evaluated using commercially available assay kits, i.e., AChE 
inhibitor screening colorimetric kit (BioVision), human β-secretase (BACE1) 
inhibitor fluorometric screening kit (BioVision), and GSK3β assay kit (BPS 
Bioscience) with Kinase-Glo (Promega) as a detection reagent. The con-
centration range of all tested compounds was selected based on the QSAR 
predictions (see Table S3 in Supplementary Material for Paper IV). All 
experiments were executed according to the manufacture’s protocols in three 
parallels in 96-well plates. For the spectroscopic measurements, Synergy M 
microplate reader (BioTek, USA) or GloMax 96 microplate luminometer 
(Promega, USA) were used. 
In the AChE inhibitor screening kit, an active hAChE enzyme hydrolyses the 
colorimetric substrate, generating a yellow chromophore, which can then be 
detected by absorbance at 412 nm in kinetic mode at room temperature for 40 
min. 
In the hBACE1 inhibitor screening kit, the activity of compounds is mea-
sured by their ability to inhibit the cleavage of a BACE1-specific substrate. The 
cleavage of the substrate by hBACE1 results in a product with high fluore-
scence that is registered in kinetic mode at 37 ºC for 90 min at Ex/Em = 
345/500 nm.  
In the GSK3β assay kit, the kinase activity is measured by quantification of 
the amount of ATP remaining in solution following the kinase reaction. The 
generated luminescent signal is correlated with the amount of ATP in solution 
and inversely to the kinase activity. 
The values of the IC50 were calculated using GraphPad prism version 8.0 for 
Windows [171]. 
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4. RESULTS AND DISCUSSION 
4.1. GDNF mimetics 
As described in Section 1.2, the GDNF family ligands (GFLs) are of interest as 
potential therapeutic agents against neurodegenerative diseases. However, the 
use of these ligands has several problems due to their relatively large size, 
limited delivery to the central nervous system through the blood-brain barrier, 
low pharmacokinetic properties and bioavailability, and potential side and 
off-target effects [37]. 
Thus, the development of small molecules that mimic the effect of GFLs and 
activate the RET signalling pathway can solve most of these problems. As 
mentioned in Section 1.3, three small-molecule ligands that mimic neurotrophic 
effects of GDNF and may act as GFRα1 agonists have been currently reported: 
XIB4035 [92], BT13 [93], and its derivative BT18 [96] (Figure 1). Despite the 
proven activity of these compounds, their molecular mechanism of the RET 
activation is still unclear. In Paper I, potential binding sites of BT13 and BT18 
agonists in the GFRα1–RET complex were studied in detail using molecular 
docking and molecular dynamics simulations. In Paper II, a potential GFRα1 
agonist showing a different binding mode to the GFRα1–RET complex as 
compared to BT13 and BT18 was designed using the structure-based drug 
design (SBDD) approach. 
 
Figure 1. Chemical structures of small-molecule ligands XIB4035, BT13, and BT18. 
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4.1.1. Molecular modelling of the interactions between GDNF 
family receptor GFRα1 and small-molecule ligands 
In Paper I, a possible mechanism of action of the known GFRα1 agonists was 
elucidated based on the computational molecular modelling. The crystal 
structure of GDNF–GFRα1–RET complex (PDB ID: 4UX8 [119]) was used in 
this study. Three possible binding regions were examined in this complex: a 
potential binding site of GFRα1 with GDNF as region A; a potential binding 
site of RET (cadherin-like domains 1 and 2) with GFRα1 as region B; and a 
potential allosteric binding site in the middle of GFRα1 as region C (Figure 2). 
The crystal structure of GDNF–GFRα1 complex with a higher resolution (PDB 
ID: 3FUB [120]) was used as a control. 
 
 
Figure 2. Potential binding sites in the GDNF–GFRα1–RET complex (PDB ID: 4UX8). 
 
 
According to the molecular docking calculations, the lowest binding energy 
positions for both small-molecule ligands BT13 and BT18 were found at the 
allosteric site in binding region of GFRα1. The docking scores were: -7.9 
kcal/mol for compound BT13, being 1.9 and 1.2 kcal/mol lower than for regions 
A and B, respectively; -9.8 kcal/mol for compound BT18, being 3.4 and 2.3 
kcal/mol lower than for regions A and B, respectively. The compound BT13 
formed a hydrogen bond by its sulphonyl group with the ammonium group of 
Lys327 of GFRα1, together with several hydrophobic contacts in region C 
(Figure 3E). The compound BT18 had a hydrogen bond between its methoxy 
group and the amine group of Asn40 as well as several hydrophobic interactions 
in region C (Figure 3F). 
25 
Figure 3. Calculated binding modes of the protein-ligand complexes: (A) GFRα1-BT13 
at the GDNF–GFRα1 interface, region A; (B) GFRα1–BT18 at the GDNF–GFRα1 
interface, region A; (C) RET–BT13 at the RET–GFRα1 interface, region B; (D) 
RET-BT18 at the RET–GFRα1 interface, region B; (E) GFRα1–BT13 at the allosteric 
site, region C; and (F) GFRα1–BT18 at the allosteric site, region C. Intermolecular 
hydrogen bonds are shown by green dashed lines. 
 
 
It should be noted that experimentally compounds BT13 and BT18 also act as 
RET direct agonists [93,96], although our calculations showed that the allosteric 
site of GFRα1 is the preferable binding region for both ligands. The binding  
site at RET interface with GFRα1 (region B) may become preferential in 
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membrane-bound state of RET, with altered conformation as compared to the 
protein structure in the single-particle state registered in the X-ray mea-
surements (PDB ID: 4UX8 [119]). Both ligands showed stacking (π-π) inter-
actions with Trp37 and had hydrophobic contacts with some residues of RET in 
region B (Figure 3C,D). 
 
Figure 4. Comparison of the binding of compounds BT13 and BT18 to protein struc-
tures 4UX8 (green) and 3FUB (white). (A) Structural alignment of protein structures; 
(B) compound BT13 at the GDNF–GFRα1 interface, region A; (C) compound BT18 at 
the GDNF–GFRα1 interface, region A; (D) compound BT13 at the allosteric site of 
GFRα1, region C; (E) compound BT18 at the allosteric site of GFRα1, region C. In 
each graph (B–E), the ligand conformation with protein structure 3FUB is in yellow and 
the ligand conformation with protein structure 4UX8 in red. 
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The comparison of binding poses for compounds BT13 and BT18 was carried 
out using the crystal structure of GDNF–GFRα1 complex (PDB ID: 3FUB 
[120]) and the results are presented in Figure 4. The binding modes of both 
ligands were almost identical at the GDNF−GFRα1 interface (Figure 4B,C), but 
somewhat different at the allosteric site (Figure 4D,E). This difference can be 
explained by the fact that the full structure of GFRα1 consists of three domains 
(D1, D2, and D3) in 4UX8 [119], however, GFRα1 in 3FUB does not have 
domain D1 that is not needed for GDNF binding [46], but it binds to RET. The 
full analysis of all binding modes is given in Table S1 in the Supporting 
Information of Paper I. 
The docking calculations were followed by the MD simulations of com-
pounds BT13 and BT18 at the three potential binding sites in regions A, B, and 
C of the GFRα1, respectively. The RMSD variations of the atomic positions 
were used for estimating the stability of the ligand binding. The MD calculated 
variations of this parameter were significantly larger for the complexes of 
compounds BT13 and BT18 in regions A and B as compared to the binding in 
region C of GFRα1. The RMSD of the complexes in region C were 6.4 Å for 
BT13 and 8.0 Å for BT18, respectively (see Figure S1a-f in the Supporting 
Information of Paper I). Thus, in accordance with the molecular docking results, 
the MD simulations also predicted the allosteric binding site in region C as 
preferable for compounds BT13 and BT18. 
The amino acid residual structure of the binding modes of ligands BT13 and 
BT18 was also identified using the MD simulations. An analysis of the 
interactions between the ligands and the protein at the allosteric site showed that 
the compound BT13 formed hydrogen bonds with the amino acid residues 
Phe41 and Thr265 of GFRα1, complemented with significant hydrophobic 
contacts around protein residues Lys251 to Phe264, and several interactions 
over the water molecule bridges (Figure 5A). The computational model of the 
compound BT18 binding mode showed its long-term hydrophobic contact with 
the protein residue Phe41 (almost 100% of the simulation time), some other 
hydrophobic interactions around protein residues Leu244 to Phe264, several 
water-assisted interactions, and a specific π-cation contact with Lys251 (Figure 
5B). 
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Figure 5. Molecular dynamics calculated protein–ligand contacts at the allosteric site, 
region C: (A) GFRα1–BT13; (B) GFRα1–BT18. Protein ID: 4UX8. 
 
The MD computed binding modes of compounds BT13 and BT18 at regions A 
and B of GFRα1 were quite similar to those obtained from the docking calcu-
lations and are presented in the Supporting Information of Paper I (Figures S2 
and S3, respectively). 
The binding energy calculations using MM/GBSA method also indicated 
that the allosteric site at the region C of the GFRα1 structure was preferable for 
binding both studied ligands, BT13 and BT18. The calculated binding free 
energy for BT13 was -50.9 kcal/mol, being 3.4 and 2.4 kcal/mol lower as 
compared to the binding energy for regions A and B, respectively. The 
calculated binding free energy for ligand BT18 was -55.7 kcal/mol, being 5.0 
and 5.9 kcal/mol lower than that for the binding regions A and B (see Table 1 in 
Paper I). 
The MD simulations were repeated with another crystal structure of 
GDNF−GFRα1 complex (PDB ID: 3FUB [120]) for BT13 and BT18. The 
results obtained were similar for region A, but partly different for region C of 
the GFRα1 structure. As mentioned above, GFRα1 does not have domain D1 in 
structure 3FUB, but according to our molecular docking and MD calculations 
with structure 4UX8, domain D1 may affect the binding of a small-molecule 
ligand at the allosteric site of GFRα1 (region C). It can be also significant in 
determining the signalling-related conformational changes. 
Additional MD simulations using AMBER package with a different force 
field were carried out by A. T. García-Sosa in order to verify the binding of 
BT13 at the allosteric binding site of GFRα1 (see details in Paper I). The 
obtained results were consistent with the Desmond MD results. 
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In conclusion, our docking calculations and MD simulations demonstrated 
that the preferable binding of compounds BT13 and BT18 may take place at the 
allosteric site of GFRα1. The complexes of BT13 and BT18 with GFRα1 were 
stable throughout several long MD simulation times. As noted above, both 
studied compounds act experimentally as RET direct agonists. The binding site 
at RET interface with GFRα1 (region B) probably becomes preferable in the 
membrane-bound state of RET. This enables BT13 and BT18 to act as direct 
agonists of RET. However, the computationally predicted binding of the studied 
compounds to either component of GDNF receptor complex (coreceptor or 
RET) involves the rather loose and nonspecific hydrophobic and van der Waals 
interactions and the favoured binding site is rather flat. Therefore, it might not 
be easy to increase the binding efficiency of the ligands as even minor modifi-
cations in the ligand structures can lead to substantial changes in their binding 
mode and inactivation.  
 
 
4.1.2. Novel small-molecule ligands  
as potential GDNF family receptor agonists 
In Paper I, an allosteric site of GFRα1 was identified as preferable for binding 
compounds BT13 and BT18. In Paper II, a novel potential GFRα1 agonist with 
a different molecular mechanism of action was designed.  
Our analysis of the binding interface between GDNF and GFRα1 using the 
available crystal structures of the GDNF–GFRα1 complex (PDB ID: 4UX8 
[119], 3FUB [120]) enabled to identify the key residues of GFRα1 for 
interaction with potential small-molecule ligands in the region A of the GFRα1 
structure (Figure 2). A potential GFRα1 agonist should be bound in the region 
of amino acid residues Arg171, Thr179, Arg224, and Gln227, forming 
hydrogen bonds to Arg171, Arg224 and/or Gln227 (see Figure 2 in Paper I). 
This is in accordance with the previously published data [172,173] on 
site-directed mutagenesis and mutants. Based on this information, four groups 
of small-molecule ligands belonging to 10 different scaffolds were examined 
(Figure 6) using a structure-based drug design (SBDD) approach. All studied 
compounds were docked in the selected area of GFRα1 (see Table S2 in the 
Supporting Information of Paper II). 
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Figure 6. Structures of small-molecule ligands used in the molecular docking to 
receptor GFRα1. 
 
The first group of compounds consisted of 28 molecules (Figure 6A,B). The 
calculated binding energies of these ligands were in the range of -4.3 to  
-5.6 kcal/mol. Only one heterocyclic compound 25 from this group exhibited 
specific binding to GFRα1 (i.e., a hydrogen bond with the amine group of 
Arg171, Figure 7A). The second group consisted of 46 structures (Figure 6C-F) 
with the binding energies ranging between -4.4 to -5.2 kcal/mol. Most of these 
compounds formed hydrogen bonds with GFRα1 via carboxyl oxygens and/or 
by the added polar substituent at the R2 position, by the nitrogen atom of the 
aromatic cycle, and by an oxygen atom of the sulphonate group (see compound 
42 in Figure 7B). The third group of constructed ligands included 8 molecules 
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with the calculated binding energies in the range of -5.0 to -6.1 kcal/mol. In this 
group, compound 77 displayed a different binding mode, forming three hydro-
gen bonds with GFRα1, involving its carboxyl oxygen with the amine group of 
Arg224, its hydroxypropyl group with the amine group of Gln227, and its 
hydroxyl group with the carbonyl oxygen of Thr228, respectively (Figure 7C). 
 
 
Figure 7. Calculated binding modes of compounds 25 (A), 42 (B), 77 (C), and 86 (D) in 
the active site of GFRα1. Intermolecular hydrogen bonds are shown by green dashed 
lines. 
 
The docking results for the first three groups of ligands, indicated that (1) com-
pounds with rigid aromatic ring(s) give lower binding energies than compounds 
with flexible cycles; (2) hydrogen bonding substituents, such as carboxyl or 
hydroxyl groups may bind to specific amino acid residues of GFRα1. 
The fourth group of ligands was constructed following these indications. 
This group included 10 compounds (Figure 6I,J). Although the free binding 
energies of these ligands were the lowest, in the range of -5.5 to -6.4 kcal/mol, 
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only one hydrogen bond was formed between the carboxyl oxygen atoms of 
ligands and the amine group of Arg224 residue of GFRα1 (see compound 86 as 
an example in Figure 7D). 
 
 
Figure 8. Selected compounds for biological experiments. 
 
The activity of compounds 107 and 118 was also confirmed by RET phospho-
rylation (pY) assays carried out by LMN in Helsinki using western blotting. 
Compound 107 activated RET pY in the cells expressing GFRα1–RET but not 
in the cells expressing only RET. Compound 118 failed to activate RET pY that 
can be explained by the differences in the sensitivity of assays. According to the 
experimental results, compound 107, similarly to GDNF, might require the pre-
sence of GFRα1 coreceptor to simulate RET pY. Surprisingly, the meta-
substituted compound 108, the analogue of para-substituted compound 107, 
showed no activity in biological experiments. Compounds 119 and 120, 
analogues of compound 118, were also inactive. According to the docking 
results, all selected compounds had almost the same binding mode in the active 
centre of GFRα1 (Figure 9). This may indicate that the relative position of the 
carboxyl group is important for biological activity.  
The designed compounds from the last group were used as templates for the 
similarity search in ZINC [174] and MolPort [175] databases. Five compounds 
were selected for further biological experiments (Figure 8). The biological 
experiments were carried out by Y. Sidorova and M. Saarma from Laboratory 
of Molecular Neuroscience (LMN), Institute of Biotechnology, HiLIFE, Uni-
versity of Helsinki. They found that compounds 107 and 108 activated luciferase 
by more than 1.5 times using luciferase assay in cells expressing GFRα1–RET 
[176]. In dose-dependent experiments, compound 107 led to moderate activa-
tion of luciferase in 25 μM and 50 μM concentrations, compound 118 demon-
strated borderline activation of luciferase in 50 μM concentration. 
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Figure 9. Calculated binding modes of compounds 107 (A), 108 (B), 118 (C), 119 (D), 
and 120 (E) in the active site of GFRα1. Intermolecular hydrogen bonds are shown by 
green dashed lines. 
 
The binding mode of compound 107 was also studied by the complementary 
molecular dynamics modelling. According to the MD results, this compound 
formed strong hydrogen bonds by its carboxyl groups with Arg224 and Thr228 
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in the GFRα1 structure. The benzimidazole rings of the ligand were also fixed 
by the water-assisted interactions with Glu223 and Gln227 in the active site of 
GFRα1 (Figure 10). 
 
Figure 10. Molecular dynamics calculated binding mode of compound 107. 
 
Thus, a potential GFRα1 agonist was designed using SBDD and molecular mo-
delling methods. Compound 107 is very different from the earlier reported 
active compounds XIB4035 [92], BT13 [93], and BT18 [96]. This is not 
surprising, as it corresponds to a different mechanism of RET activation. 
Therefore, the 2,2'-(1,4-phenylene)bis-1H-benzimidazole backbone of com-
pound 107 can be used as a new scaffold for the development of efficient 
GFRα1 agonists. 
 
 
4.2. Combination of QSAR and  
molecular modelling methods 
Molecular modelling and quantitative structure-activity relationship (QSAR) 
methods are two important computational tools in drug development. Each of 
them has its advantages and restrictions of application. The molecular docking, 
virtual screening, and MD simulations are preferably used when the 3D struc-
ture of selected protein target is known [177]. The QSAR methods do not have 
this restriction, but biological experimental data are needed to develop QSAR 
models and further predictions. The combination of these methods enables to 
utilize the advantages of both methods. For example, potential inhibitors 
identified by QSAR prediction models can be used to obtain a highly focused 
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libraries of compounds. In a similar work by Ambure et al. [178], it was showed 
that a combination of different in silico techniques can lead to fast and reliable 
results. 
In Paper III, several novel scaffolds for three target proteins – tropomyosin 
receptor kinase A (TrkA), N-methyl-D-aspartate receptor (NMDA), and 
leucine-rich repeat kinase 2 (LRRK2) – were predicted using the combination 
of machine learning and molecular modelling methods. 
In Paper IV, this approach was used to identify potential multitarget com-
pounds, which may act against Alzheimer’s disease and simultaneously aim to 
several protein targets, i.e., acetylcholinesterase (AChE), serotonin transporter 
(SERT), beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), and 
glycogen synthase kinase 3 beta (GSK3β). AChE has proven to be the most 
potent therapeutic target for the symptomatic improvement in Alzheimer’s 
disease, as cholinergic deficit is a consistent and early finding in AD [179]. 
GSK3β is considered as a critical molecular link between the senile plaques and 
neurofibrillary tangles two histopathological hallmarks of AD [180]. According 
to the amyloid cascade hypothesis, BACE1 is also considered as a major thera-
peutic target in the treatment of neurodegenerative diseases because of the 
accumulation of Aβ neurotoxic oligomers is a critical molecular event in the 
pathogenesis of AD [181]. Most publications dealing with the role of serotonin 
receptors in AD focus on the possible interaction between the serotonergic 
system and the amyloid-mediated part of pathophysiology, i.e., the interaction is 
strongly related to the sodium-dependent serotonin transporter (5-HT trans-
porter) [182]. 
 
 
4.2.1. Identification of natural compounds against 
neurodegenerative diseases using in silico techniques 
The aim of this study was to identify new potentially active compounds among 
natural products for three protein targets: TrkA, NMDA, and LRRK2. The 
studied protein targets are related to various neurodegenerative diseases, such as 
AD, PD, and neuropathic pain. It has been shown that mutations in LRRK2 are 
the most common cause of PD [183]. In the case of AD, the synaptic loss, 
deposition of Aβ plaques, neurofibrillary tangles, and hyperphosphorylated tau 
are associated with NMDA receptor activation and oxidative stress, which 
ultimately result in AD pathology [184,185]. Tyrosine kinase receptors play an 
important role in neuronal survival, together with nerve growth factors 
associated with AD and intractable pain. Therefore, along with others, the 
high-affinity receptor TrkA is considered as a target to treat neurodegenerative 
diseases [186,187]. 
A subset of natural compounds containing nearly 17,000 compounds (after 
pre-processing this number was reduced to 13,648) was obtained from ZINC 
database [174]. The development of QSAR models, virtual screening, and 
prediction of logIC50 values of the selected compounds was carried out by D. A. 
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Dobchev (see detailed information in Paper III, Sections 2.1, 2.2, and 2.3). The 
best multilinear regression (BMLR) algorithm and several back-propagation 
neural network models with different architectures were applied in the 
development and prediction of QSAR models. The top 100 compounds with the 
best predicted logIC50 by both artificial neural networks (ANN) and BMLR 
models were selected for further averaged prediction by both models. In result, 
three sets of compounds for each target were identified. The top 40% of com-
pounds (80 compounds for NMDA and LRRK2 and 40 for TrkA) predicted by 
the QSAR models for each protein target were further studied using molecular 
docking. Based on the docking results, three best compounds for each target 
were selected for further molecular dynamics study. The known inhibitors of 
NMDA (GNE-5729) [188], LRRK2 (PF-06447475) [189], and TrkA (AZ-23) 
[190] were used as a positive control. It should be noted that all selected com-
pounds had similar or somewhat smaller binding energies or ligand efficiencies 
compared to those for the known inhibitors (Table 3). The best selected com-
pounds had also similar binding modes at the active sites of the respective 
receptors. The binding modes of the selected compounds were confirmed by the 
results from 50 ns MD simulations. In the case of LRRK2, the stability of MD 
simulations in time was verified by additional runs of 20, 40, and 60 ns for 
compound 1L. The stability of the protein-ligand complexes was evaluated by 
the RMSD. This parameter varied between 1 and 4 Å for NMDA (except for 
compound 2N, which had change at about 35 ns), between 0.8 and 3.6 Å for 
LRRK2, and between 1 and 4.5 Å for TrkA (Paper III). 
In the case of NMDA, the binding mode of the ligands to NMDA calculated 
by molecular dynamics was notably different from that obtained using mole-
cular docking. The binding modes of compound 3N and the known inhibitor 
GNE-5729 (Figure 11A,B) were similar, involving hydrophobic contact with 
Tyr144, strong water-assisted interaction with the sidechain of Glu132, and 
strong hydrogen bonding with the backbone of Pro129 residue of the NMDA 
protein. The binding poses of compounds 1N and 2N were also very different, 
being directed mostly by hydrophobic interactions and water-assisted contacts. 
In the case of LRRK2, the contacts of compounds 2L and 3L involved 
strong hydrogen bonds with the amino acid residues of Glu100 and/or Leu102, 
similarly to the known inhibitor PF-06447475 (Figure 11C,D). The binding 
pose of compound 1L was different, involving two strong hydrogen bonds with 
Ser34 and Asp162. However, compound 1L was bound to the active site of 
LRKK2 and may also act as an inhibitor. 
In the case of TrkA, the calculated binding modes of compounds 1T and 3T 
were similar to the binding mode of the known inhibitor AZ-23. Both com-
pounds formed strong hydrogen bonds with the backbone of Met592 and long-
term hydrophobic contacts with Phe589, Leu657, and Val524 (Figure 11E,F). 
The binding picture of positively charged compound 2T was different, forming 
strong hydrogen bond with Asp668 and specific π−π interaction with the 
sidechain of Phe589. 
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Figure 11. Molecular dynamics calculated contacts between NMDA and GNE-5729 
(A), NMDA and compound 3N (B), LRRK2 and PF-06447475 (C), LRRK2 and 
compound 3L (D), TrkA and AZ-23 (E), TrkA and compound 3T (F). 
 
The interaction energies between the small-molecule ligands and the studied 
proteins were also estimated using MM/GBSA method [191] (Table 4). The 
comparison of the MM/GBSA calculated binding energies with those for the 
39 
known inhibitors revealed that the NMDA inhibitor GNE-5279 had signifi-
cantly better binding energy than any of the newly predicted compounds. How-
ever, the ligand efficiency of compound 2N was sufficiently high and this com-
pound may be of interest as a new potential inhibitor of NMDA. Notably, 
compound 1L from the LRRK2 set had significantly better binding energy and 
ligand efficiency than the known inhibitor PF-06447475. Therefore, this com-
pound was predicted as a potential new strong inhibitor of LRRK2. Compound 
3L may also be of interest as a potential LRRK2 inhibitor because its binding 
energy and ligand efficiency were comparable to those of the known inhibitor. 
In the case of TrkA, the binding free energy calculations showed that com-
pounds 2T and 3T and inhibitor AZ-23 had close ligand efficiencies. Con-
sequently, these compounds could be tested as potential TrkA inhibitors. 
 
 
NMDA 
Compound GNE-5729 1N 2N 3N 
∆G  -117.25 -78.50 -87.07 -66.39 
LE 4.34 3.14 3.63 2.89 
LRRK2 
Compound PF-06447475 1L 2L 3L 
∆G  -72.41 -100.04 -63.40 -69.12 
LE 3.15 4.00 2.76 3.01 
TrkA 
Compound AZ-23 1T 2T 3T 
∆G -70.44 -36.13 -43.01 -69.81 
LE 2.61 1.39 2.69 2.79 
 
In conclusion, a full cycle in silico study involving QSAR modelling, molecular 
docking, and molecular dynamics simulations enabled us to identify several 
potential LRRK2, NMDA, and TrkA protein inhibitors. These compounds 
consist of solid platform for the further development of drug candidates related 
to neurodegenerative diseases. 
 
4.2.2. Potential multitarget candidates against  
Alzheimer’s disease 
The main objective of Paper IV was to develop potential candidates for multi-
target anti-AD drugs that would be active against four different proteins, namely 
AChE, BACE1, GSK3β, and SERT. A combination of molecular modelling 
Table 4. Binding free energies (∆G in kcal/mol) and ligand efficiencies (LE) of the 
complexes between the ligand and NMDA, LRRK2 or TrkA calculated using the  
MM/GBSA method. 
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(molecular docking, MD simulations), multilinear regression statistical analysis, 
and ANN methods was used for identification of potential multitarget drug 
candidates. The general workflow included the following steps: 
1. Preparation of the training set for the development of QSAR models and 
preparation of protein target structures and compounds library; 
2. Development of QSAR models; 
3. High-throughput virtual screening (HTVS) using molecular docking of 
biogenic subset of compounds from ZINC database; 
4.  QSAR prediction of activity of the best binding compounds from HTVS; 
5. MD simulations for the best candidates for each of the studied proteins. 
The development of QSAR models and prediction of compound activities was 
carried out by D. A. Dobchev and these results are presented in Paper IV, 
Sections 2.2 and 2.3. 
The virtual docking screening was carried out using Vina [136] and Glide 
HTVS [142,143] programs. Unfortunately, Glide HTVS failed to identify com-
pounds having good binding energy and ligand efficiency for all four or three 
targets simultaneously. Additional molecular docking with Glide module at 
extra precision level of the top 60 compounds for each target did not reveal 
compounds with good binding towards several targets simultaneously and at the 
same time to satisfy Lipinski’s rule (logP not greater than 3, not more than 3 
hydrogen bond donors, hydrogen bond acceptors, and rotatable bonds) [192]. 
The virtual screening using Vina allowed to identify 57 compounds with ligand 
efficiency for each target greater or equal to 0.4. In this set, 22 compounds 
satisfied all four conditions of Lipinski’s rule, the other 35 compounds satisfied 
at least three of four criteria. 
The best binding compounds identified by Vina modelling were selected for 
further prediction of the biological activity using linear (BMLR) and non-linear 
(ANN) QSAR models. According to this prediction (see Paper IV), 5 com-
pounds (Figure 14) were selected for further experimental testing. The selection 
of potentially active compounds was based on their binding modes to the target 
protein as well as their interactions with specific amino acid residues important 
for the activity of the target protein. The most important amino acid residues of 
each target protein were identified using the MD simulations of the studied 
proteins with their known inhibitors. In the case of AChE, these inhibitors were 
(-)-huperezine A [193], donepezil [193], and (-)-galantamine [194]. The BACE1 
inhibitors used in the MD simulations included CNP520 [195], NVP-BXD552 
[196], and N-{N-[4-(acetylamino)-3,5-dichlorobenzyl]carbamimidoyl}-2-(1H-
indol-1-yl)acetamide (VTI) [197]. In the case of GSK3β, BRD0209 [198], 
PF-04802367 [199], and N-[4-(isoquinolin-7-yl)pyridin-2-yl]cyclopropane-
carboxamide (2WF) [200] were studied. The MD simulations with SERT were 
carried out using the inhibitors paroxetine [201], S-citalopram [202], and 
sertraline [203]. 
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Figure 12. Selected compounds for biological experiments. 
According to the molecular docking results, all selected compounds formed 
specific interactions with at least one key amino acid residue of each target 
protein. It is worth noting that the selected compounds had the same or even 
better binding energy/ligand efficiencies as compared to those for the known 
inhibitors (Table 5).   
Table 5. Calculated binding energies (kcal/mol) of the selected small-molecule ligands 
and the known inhibitors to target proteins (AChE, BACE1, GSK3β, and SERT). 
Compound 
Binding 
energy, ∆G 
(kcal/mol) 
LE Compound 
Binding 
energy, ∆G 
(kcal/mol) 
LE 
AChE GSK3β 
(-)-Huperezine A -7.9 0.44 2WF -7.1 0.32 
(-)-Galantamine -4.9 0.23 BRD0209 -6.9 0.27 
Donepezil -10.2 0.36 PF-04802367 -6.9 0.28 
ZINC1034491 -9.8 0.47 ZINC1034491 -8.7 0.41 
ZINC4027357 -9.3 0.44 ZINC4027357 -8.6 0.41 
ZINC3977996 -9.2 0.44 ZINC3977996 -9.1 0.43 
ZINC1763229 -9.2 0.46 ZINC1763229 -8.0 0.40 
ZINC1801081 -9.1 0.46 ZINC1801081 -8.1 0.41 
BACE1 SERT 
CNP520 -10.7 0.31 Paroxetine -10.8 0.45 
VTI -9.9 0.34 S-Citalopram -9.5 0.39 
NVP-BXD552 -9.2 0.23 Sertraline -9.1 0.46 
ZINC1034491 -10.0 0.48 ZINC1034491 -10.3 0.49 
ZINC4027357 -10.0 0.48 ZINC4027357 -10.3 0.49 
ZINC3977996 -10.2 0.49 ZINC3977996 -10.1 0.48 
ZINC1763229 -8.9 0.45 ZINC1763229 -8.9 0.44 
ZINC1801081 -9.6 0.48 ZINC1801081 -8.8 0.44 
42 
The MD simulations at the active binding site of the studied proteins showed 
similarity in the binding of the selected compounds to the known inhibitors 
(Paper IV, Section 2.6).  
According to the results of QSAR prediction and molecular modelling, 
compound ZINC3977996 can act as a multitarget inhibitor for all four targets, 
the other four compounds can act as potential inhibitors for either two or three 
targets. Specifically, compounds ZINC1034491 and ZINC1801081 can be 
potential inhibitors for AChE/GSK3β/SERT and compound ZINC4027357 can 
be a potential inhibitor for AChE/BACE1/SERT. Compound ZINC1763229 can 
be tested as a potential inhibitor for GSK3β and SERT. 
These selected compounds were further tested in the enzyme inhibition 
assays at concentrations ranging from 0.04 to 25 μM against AChE, BACE1, 
and GSK3β. Among the predicted potential inhibitors, only compound 
ZINC4027357 exhibited significant activity against two studied proteins, AChE 
and BACE1 (IC50 = 0.55 μM and 5.2 μM, respectively). Compounds 
ZINC1801081 and ZINC3977996 showed moderate inhibitory activity against 
AChE at a concentration greater than 20 μM.  
Thus, a combination of different QSAR methods and molecular modelling 
allowed to identify a new potential multitarget agent against two proteins 
associated with Alzheimer’s disease that would be valuable starting compound 
in further development of multitarget drugs against Alzheimer’s disease. 
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SUMMARY 
The main objective of the current thesis was to identify and develop active com-
pounds against the biological targets related to neurodegenerative diseases and 
to study their mechanism of the action using different molecular modelling 
methods. The basic tools used in this work were high-throughput virtual 
screening based on molecular docking and molecular dynamics simulations.  
The first part of this work involved a detailed study of the mechanism of 
interaction and binding between glial cell line-derived neurotrophic factor 
(GDNF) family receptor GFRα1 and its previously discovered BT13 and BT18 
agonists as well as the development of small molecules that mimic the effects of 
GDNF. GDNF binds to GFRα1 and then this complex binds to transmembrane 
receptor tyrosine kinase RET triggering intracellular signalling. In Paper I, the 
mechanism of action of the known agonists BT13 and BT18 on the protein 
GFRα1 was studied using molecular docking and molecular dynamics simula-
tion approaches. An allosteric site was identified in GFRα1 as preferential for 
the binding of these ligands. However, considering that the studied compounds 
have been shown experimentally to be direct GDNF signalling receptor RET 
agonists, it can be assumed that the binding site at the RET interface with 
GFRα1 becomes preferable in the membrane-bound state of RET. In this case, 
these compounds are enabled to act as direct agonists. Nevertheless, this 
elucidation of the detailed mechanism of interaction between the known active 
ligands and the GFRα1 and RET receptor complex enables further rational 
design of highly effective GDNF mimicking small molecules. The structure- 
based drug design approach was successfully applied in Paper II to find out a 
new potential GDNF family receptor agonist with a different mechanism of 
RET activation. Despite its moderate biological activity according to the 
experimental measurements, it is the first compound directly activating GDNF 
receptor RET via GFRα1 coreceptor in the absence of endogenous neurotrophic 
factor, which makes it more selective than the previously described compounds 
BT13 and BT18. 
The second part of this study focused on the application of a combination of 
QSAR and molecular modelling methods in the development of new drug 
candidates against neurodegenerative disorders. In Paper III, a subset of natural 
compounds was passed through a full cycle of an in silico study. As a result, 
several new scaffolds of the compounds were detected for protein targets 
NMDA, LRRK2, and TrkA related to Alzheimer’s disease, Parkinson’s disease, 
and neuropathic pain, respectively. A combination of different QSAR methods 
and molecular modelling as well as experimental measurements were applied in 
Paper IV to search active inhibitors against protein targets AChE, SERT, 
BACE1, and GSK3β that are related to Alzheimer’s disease. A new potential 
multitarget agent against two protein targets (AChE and BACE1) with activity 
in the micromolar range was identified. The chemical modifications of all 
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identified compounds could lead to novel drug candidates against the studied 
protein targets. 
In conclusion, eight protein targets related to several neurodegenerative 
diseases were studied. The discovered novel active compounds belonging to 
different chemical scaffolds can serve as a basis for the further development of 
drugs for the treatment of neurodegenerative diseases as well as for a deeper 
understanding of the pathogenesis and the mechanisms of the development of 
these disorders. 
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SUMMARY IN ESTONIAN 
Aktiivsete ühendite disain  
neurodegeneratiivsete haiguste raviks 
Erinevalt enamikust keharakkudest suur osa inimese närvirakke ei uuene. Vana-
nemine, vigastused ja neurodegeneratiivsed haigused põhjustavad närvirakkude 
kängumist ja surma. Levinumate neurodegeneratiivsete haiguste hulka kuuluvad 
Parkinsoni tõbi, Alzheimeri tõbi, amüotroofne lateraalskleroos, Huntingtoni tõbi 
ja dementsus. Maailma Terviseorganisatsiooni (WHO) aruande kohaselt oli 
2015. aastal dementsusehaigete koguarv maailmas 47 miljonit inimest, 2030. 
aastaks võib see kasvada 75 miljonini ja 2050. aastaks 132 miljonini. Samuti on 
WHO andmetel Alzheimeri tõbi ja teised dementsuse vormid maailmas kümne 
peamise surmapõhjuse hulgas. Väga suureks probleemiks on nende haiguste 
õigeaegne diagnoosimine haiguse algfaasis. Praegused raviks kasutatavad ravi-
mid ja ravimeetodid ainult leevendavad haigustunnuseid, kuid ei suuda kõrval-
dada haiguse põhjust ega pidurdada või peatada haiguse kulgu. Seega pakuvad 
väga suurt huvi otsingud uute ravimite leidmiseks. 
Arvutitehnoloogia areng viimastel aastakümnetel on aidanud oluliselt kiiren-
dada uute ravimite väljatöötamise pikka protsessi ja vähendada selle kulusid. 
Käesolevas doktoritöös rakendati tänapäevaseid molekulaarse modelleerimise 
meetodeid uute aktiivsete ühendite väljatöötamiseks neurodegeneratiivsete hai-
gustega seotud bioloogiliste märklaudade, erinevate ensüümide ja retseptor-
valkude vastu. 
Töö esimeses osas viidi läbi gliia närvikasvfaktori GDNF perekonna retsep-
tori GFRα1 ja selle varem leitud agonistide BT13 ja BT18 omavahelise toime ja 
seondumise mehhanismide detailne uuring ning otsingud leidmaks GDNFi toi-
met matkivaid keemilisi ühendeid ehk mimeetikuid. GDNF seondub spetsiifili-
selt retseptorile GFRα1 ja see kompleks omakorda seondub transmembraanse 
türosiini kinaasi retseptorile RET, aktiveerides rakusisesed signaalirajad. Artik-
lis I leiti, et allosteeriline sait GFRα1 valgus on eelistatud ühendite BT13 ja 
BT18 seondumisel GDNF-GFRα1-RET kompleksiga. Arvestades, et uuritud 
ühendid on eksperimentaalselt kirjeldatud ka kui otsesed RET agonistid, võib 
siiski eeldada, et RET seondumiskoht GFRα1-ga muutub eelistatavaks memb-
raani seotud RET-olekus. See võimaldaks neil ühenditel toimida otseste RET 
agonistidena. Artiklis II kasutati struktuuri-põhist ravimidisaini, leidmaks uut 
potentsiaalset GDNFi perekonna retseptori GFRα1 agonisti, millel on erinev 
RET aktiveerimise mehhanism. Kuigi leitud ühend on bioloogiliselt väheaktiiv-
ne, on see siiski esimene ühend, mis aktiveerib otseselt GDNFi retseptorit RET 
retseptori GFRα1 kaudu endogeense närvikasvufaktori puudumisel, mis muu-
dab selle selektiivsemaks kui varem kirjeldatud ühendid BT13 ja BT18. 
Töö teises osas rakendati struktuur-omadus sõltuvustel (QSAR) põhinevate 
ja molekulaarse modelleerimise meetodite kombinatsiooni uute ravimikandi-
daatide väljatöötamisel neurodegeneratiivsete haiguste vastu. Artiklis III uuriti 
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in silico looduslikke ühendeid, mille tulemusena tuvastati vastavalt Alzheimeri 
tõve, Parkinsoni tõve ja neuropaatilise valuga seotud sihtmärkide NMDA, 
LRRK2 ja TrkA jaoks mitmed uued potentsiaalsete inhibiitorite kandidaadid. 
Artiklis IV otsiti ravimikandidaate, lähtudes erinevatest Alzheimeri tõvega seo-
tud valgu sihtmärkidest AChE, SERT, BACE1 ja GSK3β. Tuvastati ühend, mis 
toimib mikromolaarse inhibeeriva aktiivsusega kahe sihtmärgi (AChE ja 
BACE1) vastu. Leitud ühendite molekulaarse struktuuri edasine optimeerimine 
võimaldab leida uusi efektiivseid ravimikandidaate uuritud sihtvalkude vastu. 
Kokkuvõtvalt, käesoleva doktoritöö käigus uuriti kaheksat neurodegenera-
tiivsete haigustega seotud valgu sihtmärki. Saadud andmed ja leitud uued aktiiv-
sed ühendid võivad olla aluseks neurodegeneratiivsete haiguste raviks mõeldud 
ravimite edasisel väljatöötamisel, samuti nende haiguste arengu ja tekkemehha-
nismide sügavamal mõistmisel. 
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